Key Stats for Illumina Stock
- Past-Week Performance: +4.5%
- 52-Week Range: $68.7 to $155.5
- Current Price: $123.3
What Happened?
After genomics leader Illumina (ILMN) posted clinical consumables growth of 20% outside China in Q4 2025, its sequencing instruments now number 890 globally, and the stock at $124.33 sits closer to its 52-week high of $155.53 than its low of $68.70.
Illumina’s Q4 2025 earnings, reported February 5, delivered total revenue of $1.16 billion, beating expectations, with non-GAAP EPS of $1.35 growing 42% year-over-year and full-year free cash flow of $931 million validating the cost restructuring begun in 2024.
Clinical consumables, the segment tracking revenue from cancer and genetic disease testing kits run on Illumina sequencers, grew roughly 16% outside China in H2 2025 and drove total sequencing gigabase output up more than 30% year-over-year on connected high- and mid-throughput instruments.
On March 18, Illumina and Labcorp expanded their precision oncology partnership to co-commercialize Labcorp’s FDA-authorized liquid biopsy assay PGDx elio plasma focus Dx alongside Illumina’s FDA-approved TruSight Oncology Comprehensive, a panel used to identify cancer-driving mutations in solid tumors, while also developing new in-vitro diagnostic tests covering comprehensive genomic profiling and whole-genome sequencing.
Moreover, Chief Executive Jacob Thaysen stated on the Q4 2025 earnings call that “clinical remains our primary growth driver, and higher testing volumes with more sequencing-intensive applications reinforces demand for high-throughput, high-quality sequencing on the NovaSeq X,” tying directly to the February 24 launch of TruPath Genome, a whole-genome workflow priced at $395 per sample that eliminates traditional library preparation.
Illumina targets 2026 revenue of $4.5 billion to $4.6 billion, non-GAAP EPS of $5.05 to $5.20, and an operating margin of 23.3% to 23.5%, advancing toward a 26% margin target in 2027 alongside its January 30 SomaLogic acquisition, which adds aptamer-based protein analysis covering roughly 9,500 proteins and extends Illumina’s multiomics capabilities beyond DNA sequencing into the proteome.
Wall Street’s Take on ILMN Stock
The 20% clinical consumables growth outside China that Illumina posted in Q4 2025 directly supports the 2026 guidance for double-digit to mid-teens clinical expansion, which drives the EBITDA margin expansion from 27.8% in 2025 toward 29.5% in 2026 estimated by TIKR.
TIKR models normalized EPS growing from $4.84 in 2025 to $5.85 in 2027, a 14.3% annual gain, anchored by EBIT margins recovering to 24.8% as the NovaSeq X platform transition completes and clinical volume absorbs a larger share of fixed costs.
Fourteen analysts cover the stock, and 9 rate it buy or outperform against 8 holds, with a mean price target of $136.05 implying 9.4% upside from $124.33, though analysts are specifically watching the clinical consumables trajectory and the NIH funding environment as the two variables most likely to move that consensus.
The analyst target range of $80 to $170 reflects genuine binary optionality: the $170 high anchors to mid-teens clinical growth sustaining through 2026, while the $80 low reflects a scenario where NIH funding deterioration accelerates research declines and the SomaLogic acquisition, which Illumina paid $350 million to close January 30, dilutes margins further than the guided 100 basis points.
What Does the Valuation Model Say?
The TIKR mid-case price target of $200.60 by December 2030, implying a 10.5% annualized return, rests on a 5.5% revenue CAGR and net income margins recovering to 22.3%, a level already validated by the 2021 baseline of 19.7% before the Grail-related cost overhang compressed earnings to 3% in 2023.
The market appears to be pricing Illumina as a low-growth sequencing hardware company, ignoring that normalized EPS already doubled from $2.45 in 2024 to $4.84 in 2025.
Clinical consumables now growing 20% outside China and the NovaSeq X installed base reaching 890 instruments directly justify TIKR’s $200.60 mid-case target by sustaining the volume ramp that drives margin leverage.
Management guiding to 26% operating margins by 2027 and committing to another 130 basis points of expansion in 2026 confirms this is an operational re-rating story, not a cyclical bounce.
The primary model risk is the research and academic segment, where mid-to-high single-digit declines are already embedded in guidance; a further NIH funding deterioration would compress consumables growth and delay the operating leverage that underpins the $5.85 normalized EPS estimate for 2027.
Q1 2026 results, where management guided $1.06 billion to $1.08 billion in revenue and EPS of $1.02 to $1.07, will be the first test of whether clinical momentum held through the quarter and whether the SomaLogic dilution tracks the guided $0.04.
Should You Invest in Illumina, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ILMN stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Illumina, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ILMN stock on TIKR for Free →
